Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Sep 22;58(10):e01361-20.
doi: 10.1128/JCM.01361-20. Print 2020 Sep 22.

Evaluation of Six Commercial Mid- to High-Volume Antibody and Six Point-of-Care Lateral Flow Assays for Detection of SARS-CoV-2 Antibodies

Carmen L Charlton #  1   2   3 , Jamil N Kanji #  4   5 , Kam Johal  4 , Ashley Bailey  4 , Sabrina S Plitt  6 , Clayton MacDonald  4   2 , Andrea Kunst  7 , Emily Buss  7 , Laura E Burnes  4   2 , Kevin Fonseca  4   8 , Byron M Berenger  4   9 , Kareena Schnabl  2   7 , Jia Hu  10   11 , William Stokes  12 , Nathan Zelyas  4   2 , Graham Tipples  4   3   13
Affiliations
Comparative Study

Evaluation of Six Commercial Mid- to High-Volume Antibody and Six Point-of-Care Lateral Flow Assays for Detection of SARS-CoV-2 Antibodies

Carmen L Charlton et al. J Clin Microbiol. .

Abstract

Coronavirus disease (COVID) serological tests are essential to determine the overall seroprevalence of a population and to facilitate exposure estimates within that population. We performed a head-to-head assessment of enzyme immunoassays (EIAs) and point-of-care lateral flow assays (POCTs) to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. Demographics, symptoms, comorbidities, treatment, and mortality of patients whose sera were used were also reviewed. Six EIAs (Abbott, Affinity, Bio-Rad, DiaSorin, Euroimmun, and Roche) and six POCTs (BTNX, Biolidics, Deep Blue, Genrui, Getein BioTech, and Innovita) were evaluated for the detection of SARS-CoV-2 antibodies in known COVID-19-infected individuals. Sensitivity of EIAs ranged from 50 to 100%, with only four assays having overall sensitivities of >95% after 21 days after symptom onset. Notably, cross-reactivity with other respiratory viruses (parainfluenza virus [PIV-4] [n = 5], human metapneumovirus [hMPV] [n = 3], rhinovirus/enterovirus [n = 1], CoV-229E [n = 2], CoV-NL63 [n = 2], and CoV-OC43 [n = 2]) was observed; however, overall specificity of EIAs was good (92 to 100%; all but one assay had specificity above 95%). POCTs were 0 to 100% sensitive >21 days after onset, with specificity ranging from 96 to 100%. However, many POCTs had faint banding and were often difficult to interpret. Serology assays can detect SARS-CoV-2 antibodies as early as 10 days after symptom onset. Serology assays vary in their sensitivity based on the marker (IgA/IgM versus IgG versus total) and by manufacturer; however, overall only 4 EIAs and 4 POCTs had sensitivities of >95% >21 days after symptom onset. Cross-reactivity with other seasonal coronaviruses is of concern. Serology assays should not be used for the diagnosis of acute infection but rather in carefully designed serosurveys to facilitate understanding of seroprevalence in a population and to identify previous exposure to SARS-CoV-2.

Keywords: COVID-19; SARS-CoV-2; antibody testing; serology.

PubMed Disclaimer

References

    1. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. 2020. A novel coronavirus emerging in China—key questions for impact assessment. N Engl J Med 382:692–694. doi:10.1056/NEJMp2000929. - DOI - PubMed
    1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. 2020. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 382:1199–1207. doi:10.1056/NEJMoa2001316. - DOI - PMC - PubMed
    1. World Health Organization. 2020. Coronavirus disease (COVID-19) situation report 163. https://www.who.int/docs/default-source/coronaviruse/situation-reports/2....
    1. Tang YW, Schmitz JE, Persing DH, Stratton CW. 2020. The laboratory diagnosis of COVID-19 infection: current issues and challenges. J Clin Microbiol 58:e00512-20. doi:10.1128/JCM.00512-20. - DOI - PMC - PubMed
    1. Hanson KE, Azar MM, Banerjee R, Chou A, Colgrove RC, Ginocchio CC, Hayden MK, Holodiny M, Jain S, Koo S, Levy J, Timbrook TT, Caliendo AM, Diagnostics Committee of the Infectious Diseases Society of America (IDSA). 2020. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19. IDSA. www.idsociety.org/COVID19guidelines/dx. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources